Vivianne Jakobsson

Notable Publications:

Liu N, Wan Q, Wu X, et al. A comparison of [(18)F]AlF- and (68)Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging. Eur J Nucl Med Mol Imaging. 2024;51:1685-1697.

Tan Y, Li J, Zhao T, et al. Clinical translation of a novel FAPI dimer [(68)Ga]Ga-LNC1013. Eur J Nucl Med Mol Imaging. 2024.

Baum RP, Fan X, Jakobsson V, et al. Long-term nephrotoxicity after PRRT: myth or reality. Theranostics. 2024;14:451-459.

Baum RP, Wang P, Jakobsson V, et al. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). Theranostics. 2024;14:133-142.

Baum RP, Fan X, Jakobsson V, et al. Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles. Eur J Nucl Med Mol Imaging. 2024;51:1136-1146.

Wang R, Jakobsson V, Wang J, et al. Dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics. 2023;13:2979-2992.

Zang J, Lin R, Wen X, et al. A head-to-head comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in patients with various cancers. Clin Nucl Med. 2023;48:861-868.

Tao Y, Jakobsson V, Chen X, Zhang J. Exploiting albumin as a versatile carrier for cancer theranostics. Acc Chem Res. 2023;56:2403-2415.

Shi M, Jakobsson V, Greifenstein L, et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne). 2022;9:1034315.

Zirakzadeh AA, Sherif A, Rosenblatt R, et al. Tumour-associated B cells in urothelial urinary bladder cancer. Scand J Immunol. 2020;91:e12830.